Antithrombotic dilemma.

Area of Science:

• Cardiology
• Pharmacology
• Interventional Cardiology

Background:

• Patients with mechanical heart valves or atrial fibrillation often require chronic oral anticoagulation.
• Ischemic heart disease is common in these patients, necessitating antiplatelet therapy, especially after percutaneous coronary intervention (PCI) with stenting.
• Combining warfarin with aspirin and clopidogrel (triple therapy) increases bleeding risk.

Purpose of the Study:

• To evaluate the safety and efficacy of combined antiplatelet-warfarin therapy after coronary stenting.
• To determine the optimal antithrombotic strategy balancing thrombotic and bleeding risks in this high-risk population.

Main Methods:

• The study focuses on the clinical dilemma of managing antithrombotic therapy in patients requiring both anticoagulation and dual antiplatelet therapy post-stenting.
• It highlights the lack of prospective, randomized data to guide treatment decisions.

Main Results:

• The optimal antithrombotic regimen for patients needing chronic anticoagulation and undergoing coronary stenting is not established.
• Triple therapy (warfarin, aspirin, clopidogrel) is associated with increased bleeding complications.

Conclusions:

• There is a critical need for prospective studies to define the best antithrombotic approach after coronary stenting in patients on chronic anticoagulation.
• Balancing the prevention of stent thrombosis against the risk of bleeding is a major clinical challenge.